BAO PHARMA-B (02659) Concludes Phase III Trial Follow-Up for KJ103 in Kidney Transplant Desensitization

Stock News03-25

BAO PHARMA-B (02659) has announced the completion of primary trial follow-up for all participants in the Phase III clinical study of KJ103 as a desensitization therapy for highly sensitized patients awaiting kidney transplantation in China. The follow-up period concluded on March 20, 2026. The company plans to submit a New Drug Application to the National Medical Products Administration promptly.

KJ103 is a first-in-class, low-immunogenicity innovative recombinant immunoglobulin G (IgG) degrading enzyme, developed for treating various immune-mediated diseases and conditions driven by pathological IgG antibodies. In August 2025, the company initiated the Phase III clinical trial (CTR20252973) to evaluate KJ103 for desensitization in highly sensitized renal transplant recipients, with the goal of effectively clearing pre-existing HLA antibodies and preventing hyperacute rejection.

In November 2024, KJ103 received Breakthrough Therapy Designation from the National Medical Products Administration for this specific indication.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136288467?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 13:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136288467","market":"fut","top_or_hot":-1,"title":"BAO PHARMA-B (02659) Concludes Phase III Trial Follow-Up for KJ103 in Kidney Transplant Desensitization","media":"Stock News","content":"<p>BAO PHARMA-B (02659) has announced the completion of primary trial follow-up for all participants in the Phase III clinical study of KJ103 as a desensitization therapy for highly sensitized patients awaiting kidney transplantation in China. The follow-up period concluded on March 20, 2026. The company plans to submit a New Drug Application to the National Medical Products Administration promptly.</p>\n<p>KJ103 is a first-in-class, low-immunogenicity innovative recombinant immunoglobulin G (IgG) degrading enzyme, developed for treating various immune-mediated diseases and conditions driven by pathological IgG antibodies. In August 2025, the company initiated the Phase III clinical trial (CTR20252973) to evaluate KJ103 for desensitization in highly sensitized renal transplant recipients, with the goal of effectively clearing pre-existing HLA antibodies and preventing hyperacute rejection.</p>\n<p>In November 2024, KJ103 received Breakthrough Therapy Designation from the National Medical Products Administration for this specific indication.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAO PHARMA-B (02659) Concludes Phase III Trial Follow-Up for KJ103 in Kidney Transplant Desensitization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAO PHARMA-B (02659) Concludes Phase III Trial Follow-Up for KJ103 in Kidney Transplant Desensitization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-25 13:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAO PHARMA-B (02659) has announced the completion of primary trial follow-up for all participants in the Phase III clinical study of KJ103 as a desensitization therapy for highly sensitized patients awaiting kidney transplantation in China. The follow-up period concluded on March 20, 2026. The company plans to submit a New Drug Application to the National Medical Products Administration promptly.</p>\n<p>KJ103 is a first-in-class, low-immunogenicity innovative recombinant immunoglobulin G (IgG) degrading enzyme, developed for treating various immune-mediated diseases and conditions driven by pathological IgG antibodies. In August 2025, the company initiated the Phase III clinical trial (CTR20252973) to evaluate KJ103 for desensitization in highly sensitized renal transplant recipients, with the goal of effectively clearing pre-existing HLA antibodies and preventing hyperacute rejection.</p>\n<p>In November 2024, KJ103 received Breakthrough Therapy Designation from the National Medical Products Administration for this specific indication.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1136288467","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136288467","pubTimestamp":1774416257,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BAO PHARMA-B (02659) has announced the completion of primary trial follow-up for all participants in the Phase III clinical study of KJ103 as a desensitization therapy for highly sensitized patients...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B","BK1161":"生物科技","BK4134":"信息科技咨询与其它服务","III":"信息服务"},"translate_title":"宝药业-B(02659)结束KJ103用于肾移植脱敏的III期试验随访","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1,"III":1},"content_text":"BAO PHARMA-B (02659) has announced the completion of primary trial follow-up for all participants in the Phase III clinical study of KJ103 as a desensitization therapy for highly sensitized patients awaiting kidney transplantation in China. The follow-up period concluded on March 20, 2026. The company plans to submit a New Drug Application to the National Medical Products Administration promptly.\nKJ103 is a first-in-class, low-immunogenicity innovative recombinant immunoglobulin G (IgG) degrading enzyme, developed for treating various immune-mediated diseases and conditions driven by pathological IgG antibodies. In August 2025, the company initiated the Phase III clinical trial (CTR20252973) to evaluate KJ103 for desensitization in highly sensitized renal transplant recipients, with the goal of effectively clearing pre-existing HLA antibodies and preventing hyperacute rejection.\nIn November 2024, KJ103 received Breakthrough Therapy Designation from the National Medical Products Administration for this specific indication.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136288467","isCrawlerRequest":true}